Approaches for generation of anti-leukemia specific T cells
Approaches for generation of anti-leukemia specific T cells
复制标题
抗白血病特异性 T 细胞的生成方法
DOI：
10.1016/j.cr.2018.09.002
复制
发表时间：
2018
影响因子：
--
通讯作者：
Yangqiu Li
中科院分区：
文献类型：
--
作者：
Zhenyi Jin;Ling Xu;Yangqiu Li
三十年前，有报道称，通过输注自体肿瘤浸润淋巴细胞（TILs）的过继T细胞免疫治疗可介导转移性黑色素瘤患者的客观癌症消退。自抗cd19嵌合抗原受体T细胞（CAR-T）治疗难治性和复发性B淋巴细胞白血病的改进和临床应用以来，T细胞免疫治疗进入了一个新的时代。然而，在实现通用和有效的T细胞免疫治疗的道路上仍然存在一些挑战和困难，包括缺乏从每个患者身上产生抗白血病特异性T细胞的通用方法。在此，我们总结了目前产生抗白血病特异性T细胞的方法，以及未来有希望的方法。
As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.